R21 Malaria Vaccine Dramatically Cuts Cases and Deaths Across Africa, But Funding Gaps and Misinformation Threaten Progress
カートのアイテムが多すぎます
ご購入は五十タイトルがカートに入っている場合のみです。
カートに追加できませんでした。
しばらく経ってから再度お試しください。
ウィッシュリストに追加できませんでした。
しばらく経ってから再度お試しください。
ほしい物リストの削除に失敗しました。
しばらく経ってから再度お試しください。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
-
ナレーター:
-
著者:
概要
Yet challenges persist amid funding shortfalls. CIDRAP News warns that slashed US aid via USAID has sparked malaria comebacks in burdened nations, leaving gaps as governments negotiate support. Meanwhile, Burkina Faso celebrates two years of R21 rollout, with Gavi reporting a 32% plunge in national cases from 10.8 million in 2024 to 7.3 million in 2025, and deaths falling 44% from 3,523 to 1,979. Among under-fives, cases dropped 39% and mortality over 40%, crediting four-dose schedules at 5, 6, 7, and 15 months alongside partners like UNICEF, WHO, Jhpiego, and USAID.
Misinformation threatens progress. TDR details a recent infodemic in Togo, where social media influencers spread rumors days before R21 introduction, prompting the Optimising Malaria Vaccine consortium—including TDR—to share trust-building strategies as RTS,S and R21 expand across Africa. Health Minister Robert Kargougou hailed the vaccines' role in curbing severe cases nationwide.
These developments underscore vaccines' potential to avert up to 600,000 annual deaths, per The Independent, though experts urge sustained funding and anti-misinformation efforts to sustain gains.
This content was created in partnership and with the help of Artificial Intelligence AI
まだレビューはありません